Drugs / TQB2103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05867563 | Jul 2023 → May 2025 | cancer | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB2103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05867563 ↗ |
| Modality | Other / unclassified | “TQB2103 injection is an antibody-drug conjugate (ADC) targeting claudin (CLDN) 18.2.” NCT05867563 ↗ |
| Route | Intravenous | “intravenous infusion of TQB2103 for injection once every three weeks” NCT05867563 ↗ |
| Target | CLDN18 | “TQB2103 for injection is an antibody-drug conjugate targeting CLDN18.2.” NCT05867563 ↗ |